Comprehensive Income (Loss), Net of Tax, Attributable to Parent of ArriVent BioPharma, Inc. from 31 Dec 2023 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
ArriVent BioPharma, Inc. quarterly and annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD history and change rate from 31 Dec 2023 to 31 Dec 2025.
  • ArriVent BioPharma, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 31 Dec 2025 was $35,738,000, a 71% decline year-over-year.
  • ArriVent BioPharma, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending 31 Dec 2025 was $166,083,000, a 106% decline year-over-year.
  • ArriVent BioPharma, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2025 was $166,083,000, a 106% decline from 2024.
  • ArriVent BioPharma, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2024 was $80,699,000, a 16% decline from 2023.
Source SEC data
View on sec.gov
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)

ArriVent BioPharma, Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $166,083,000 $35,738,000 -$14,894,000 -71% 01 Oct 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
Q3 2025 $151,189,000 $34,752,000 -$14,188,000 -69% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $137,001,000 $31,400,000 -$9,526,000 -44% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $127,475,000 $64,193,000 -$46,776,000 -269% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $80,699,000 $20,844,000 01 Oct 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
Q3 2024 $20,564,000 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $21,874,000 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $17,417,000 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1

ArriVent BioPharma, Inc. Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $166,083,000 -$85,384,000 -106% 01 Jan 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
2024 $80,699,000 -$11,366,000 -16% 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
2023 $69,333,000 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.